HRTX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

38.08M

+5.69%

-0.013

-79.17%

39.03M

+18.96%

-0.015

-50%

39.83M

-2.34%

-0.020

-200%

Estimates Revision

The market is revising Downward the revenue expectations for Heron Therapeutics, Inc. (HRTX) for FY2025, with the revenue forecasts being adjusted by -1.12% over the past three months. During the same period, the stock price has changed by 11.83%.

Revenue Estimates for FY2025

Revise Downward

-1.12%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+118.18%

In Past 3 Month

Stock Price

Go Up

+11.83%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast HRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRTX is 4.50 USD with a low forecast of 3.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

3.00

Averages

4.50

High

6.00

Current: 0.000

Low

3.00

Averages

4.50

High

6.00

Jefferies

Buy

downgrade

$6 -> $5

2025-11-04

Reason

Jefferies

Price Target

$6 -> $5

2025-11-04

downgrade

Buy

Reason

Jefferies lowered the firm's price target on Heron Therapeutics to $5 from $6 and keeps a Buy rating on the shares. Zynrelef delivered Q3 net revenue of $9.3M, ahead of the consensus view of $9M, driven by rising demand, vial access needle transition, improved access, and enhanced support programs, the analyst tells investors in a research note. The firm added that its price target, which is based on a DCF valuation model, is also driven by oncology franchise sales, with peak sales of $106M in 2025.

H.C. Wainwright

Brandon Folkes

Buy

initiated

2025-06-09

Reason

H.C. Wainwright

Brandon Folkes

Price Target

2025-06-09

initiated

Buy

Reason

H.C. Wainwright analyst Brandon Folkes initiated coverage of Heron Therapeutics with a Buy rating and $6 price target. Heron is a commercial-stage biotechnology company with multiple products, across the acute care and oncology supportive care setting, the analyst tells investors in a research note. The firm says Heron is entering a "meaningful inflection phase" on Zynrelef. Despite successful branded products in the post-surgical pain market, overall branded penetration remains low, contends H.C. Wainwright.

Needham

Serge Belanger

Strong Buy

Reiterates

2025-04-11

Reason

Needham

Serge Belanger

Price Target

2025-04-11

Reiterates

Strong Buy

Reason

Needham

Serge Belanger

Strong Buy

Reiterates

2025-02-28

Reason

Needham

Serge Belanger

Price Target

2025-02-28

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Heron Therapeutics Inc (HRTX.O) is -72.00, compared to its 5-year average forward P/E of -94.90. For a more detailed relative valuation and DCF analysis to assess Heron Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-94.90

Current PE

-72.00

Overvalued PE

307.47

Undervalued PE

-497.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.29

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

4.83

Undervalued EV/EBITDA

-9.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.06

Current PS

1.38

Overvalued PS

7.95

Undervalued PS

0.17

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

HRTX News & Events

Events Timeline

No data

News

9.5

14:47 PMGlobenewswire

Heron Therapeutics Reports $154.9M Net Revenue for 2025

4.0

2025-12-18NASDAQ.COM

Daily Upgrade Report for Validea's James P. O'Shaughnessy Strategy - December 18, 2025

5.0

2025-12-04Globenewswire

Heron Launches APONVIE for Rapid Prevention of Postoperative Nausea and Vomiting

People Also Watch

Frequently Asked Questions

What is Heron Therapeutics Inc (HRTX) stock price today?

The current price of HRTX is 1.465 USD — it has increased 15.35 % in the last trading day.

What is Heron Therapeutics Inc (HRTX)'s business?

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.

What is the price predicton of HRTX Stock?

What is Heron Therapeutics Inc (HRTX)'s revenue for the last quarter?

Heron Therapeutics Inc revenue for the last quarter amounts to 38.21M USD, increased 16.47 % YoY.

What is Heron Therapeutics Inc (HRTX)'s earnings per share (EPS) for the last quarter?

Heron Therapeutics Inc. EPS for the last quarter amounts to -0.10 USD, increased 233.33 % YoY.

What changes have occurred in the market's expectations for Heron Therapeutics Inc (HRTX)'s fundamentals?

How many employees does Heron Therapeutics Inc (HRTX). have?

Heron Therapeutics Inc (HRTX) has 122 emplpoyees as of January 09 2026.

What is Heron Therapeutics Inc (HRTX) market cap?

Today HRTX has the market capitalization of 232.87M USD.